fda semaglutide mash Novo Nordisk secures approval for Wegovy to treat Wegovy FDA Approval for MASH

Tirzepatide (Zepbound/Mounjaro): A dual GLP-1/GIP receptor agonist undergoing evaluation for MASH after demonstrating significant liver fat reduction in studies.Retatrutide: A "triple agonist" targeting GLP-1, GIP, and glucagon (GCGR) receptors, which has shown "unprecedented" efficacy in weight loss and is being evaluated for metabolic diseases including MASH

Hims & Hers Health (NYSE:HIMS) is expanding its GLP-1 weight-loss treatment offerings, adding new options to its telehealth platform

Prusogliptin, developed by CSPC Ouyi Pharmaceutical, is a novel oral dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved by NMPA on January 8, 2025.

Exposures New users of GLP-1RA were separately compared with new users of dipeptidyl peptidase-4 inhibitors (DPP4i) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), using 1:1 propensity score matching to adjust for differences in patient characteristics

Affordable GLP-1 weight loss medications100% online

Recent estimates suggest that as many as 12 percent of Americans are now taking GLP-1s